AVTOZMA
LaunchmAbBLAIV (INFUSION)INJECTABLE
Approved
Jan 2026
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
3/8 — Basic
AVTOZMA by Celltrion is membrane-bound il-6 receptors (sil-6r and mil-6r), and have been shown to inhibit il-6-mediated signaling through these receptors. Approved for more disease-modifying anti-rheumatic drugs (dmards), giant cell arteritis (gca) in adult patients, active polyarticular juvenile idiopathic arthritis in patients 2 years of age and 9 more indications. First approved in 2026.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVTOZMA is a monoclonal antibody (mAb) IL-6 receptor antagonist approved by the FDA on January 21, 2026, developed by Celltrion. It inhibits IL-6-mediated signaling through both membrane-bound and soluble IL-6 receptors to reduce pro-inflammatory cytokine activity. The drug treats diverse inflammatory conditions including rheumatoid arthritis, giant cell arteritis, juvenile idiopathic arthritis, CAR-T induced cytokine release syndrome, and severe COVID-19.
Launch
Early-stage launch for a novel IV biologic with multi-indication potential will require robust commercial infrastructure, MSL engagement, and field team buildout.
Mechanism of Action
membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and have been shown to inhibit IL-6-mediated signaling through these receptors. IL-6 is a pleiotropic pro-inflammatory cytokine produced by a variety of cell types including T- and B-cells, lymphocytes, monocytes and fibroblasts. IL-6 has been…
Worked on AVTOZMA at Celltrion? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.